Shares of Danish diabetes care giant Novo Nordisk (NOV: N) fell as much as 2.3% before recovering some ground to close 0.9% lower at 267.10 Danish kroner on Friday, after the company revealed it had been served with a subpoena by the office of the US Attorney for the District of Massachusetts.
The subpoena is requesting documents regarding potential manufacturing issues within certain production units located in Kalundborg, Denmark. Novo Nordisk said it is cooperating fully with the US Attorney in this investigation.
“At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information,” the company stated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze